Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2013

01-10-2013 | Review Article

Vasculitis in New Zealand

Author: Janak Rashme de Zoysa

Published in: Clinical and Experimental Nephrology | Issue 5/2013

Login to get access

Abstract

Background

The Asia Pacific Meeting for Vasculitis and ANCA Workshop was held in Tokyo in May 2012. This review of vasculitis in New Zealand (NZ) was prepared for the meeting.

Methods

A review of significant NZ demographic and health data is presented with information from relevant studies on vasculitis originating from NZ.

Results

Giant cell arteritis occurs in older adults, and has an annual incidence of 12.7/100,000 adults over the age of 50 years in NZ. Kawasaki disease, a rare cause of acquired cardiac disease primarily affecting young children, has an annual incidence of 8.0/100,000 children aged less than 5 years. The prevalence of granulomatosis with polyangiitis varies within NZ, with a 5-year prevalence varying from 29 to 75 cases per million people. Dual anti-glomerular basement membrane disease and ANCA-associated systemic vasculitis is rare, with an annual incidence estimated at 0.47 cases per million people.

Conclusions

Vasculitis is an uncommon but a significant cause of morbidity and mortality in NZ.
Literature
1.
go back to reference New Zealand in profile: 2012. Statistics New Zealand. New Zealand Government 2012. New Zealand in profile: 2012. Statistics New Zealand. New Zealand Government 2012.
3.
go back to reference McKinnon M, editor. Bateman New Zealand Historical Atlas. Albany: David Bateman Ltd; 1997. McKinnon M, editor. Bateman New Zealand Historical Atlas. Albany: David Bateman Ltd; 1997.
5.
go back to reference Abdul-Rahman AM, Molteno ACB, Bevin TH. The epidemiology of giant cell arteritis in Otago, New Zealand: a 9-year analysis. N Z Med J. 2011;124:44–52.PubMed Abdul-Rahman AM, Molteno ACB, Bevin TH. The epidemiology of giant cell arteritis in Otago, New Zealand: a 9-year analysis. N Z Med J. 2011;124:44–52.PubMed
6.
go back to reference Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann Rheum Dis. 2006;65:1093–8.PubMedCrossRef Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann Rheum Dis. 2006;65:1093–8.PubMedCrossRef
7.
go back to reference Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore). 2007;86:61–8.CrossRef Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore). 2007;86:61–8.CrossRef
8.
go back to reference Bas-Lando M, Breuer GS, Berkun Y, et al. The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin Exp Rheumatol. 2007;25(1 Suppl 44):S15–7.PubMed Bas-Lando M, Breuer GS, Berkun Y, et al. The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin Exp Rheumatol. 2007;25(1 Suppl 44):S15–7.PubMed
9.
go back to reference Elling P, Olsson AT, Elling H. Synchronous variations in the incidence of temporal arteritis and polymyalgia rheumatica in Danish counties. Association with epidemics of Mycoplasma pneumonia infection. Ugeskr Laeger. 1997;159:4123–8.PubMed Elling P, Olsson AT, Elling H. Synchronous variations in the incidence of temporal arteritis and polymyalgia rheumatica in Danish counties. Association with epidemics of Mycoplasma pneumonia infection. Ugeskr Laeger. 1997;159:4123–8.PubMed
10.
go back to reference Salvarani C, Crowson CS, O’Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthr Rheum. 2004;51:264–8.CrossRef Salvarani C, Crowson CS, O’Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthr Rheum. 2004;51:264–8.CrossRef
11.
go back to reference Heaton P, Wilson N, Nicholson R, Doran J, Parsons A, Aiken G. J Paediatr Child Health. 2006;42:184–90.PubMedCrossRef Heaton P, Wilson N, Nicholson R, Doran J, Parsons A, Aiken G. J Paediatr Child Health. 2006;42:184–90.PubMedCrossRef
12.
go back to reference Gibson A, Stamp LK, Chapman PT, O’Donnell JL. The epidemiology of Wegener’s granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology. 2006;2006(45):624–8.CrossRef Gibson A, Stamp LK, Chapman PT, O’Donnell JL. The epidemiology of Wegener’s granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology. 2006;2006(45):624–8.CrossRef
13.
go back to reference Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua C, Bentham G, Scott DGI. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis. 2001;60:170.PubMedCrossRef Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua C, Bentham G, Scott DGI. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis. 2001;60:170.PubMedCrossRef
14.
go back to reference O’Donnell JL, Stevanovic VR, Frampton C, Stamp LK, Chapman PT. Wegener’s granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Intern Med J. 2007;37:242–6.PubMedCrossRef O’Donnell JL, Stevanovic VR, Frampton C, Stamp LK, Chapman PT. Wegener’s granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Intern Med J. 2007;37:242–6.PubMedCrossRef
15.
go back to reference de Zoysa J, Taylor D, Thein H, Yehia M. Incidence and features of dual anti-GBM positive and ANCA positive patients. Nephrology. 2011;16:725–9.CrossRef de Zoysa J, Taylor D, Thein H, Yehia M. Incidence and features of dual anti-GBM positive and ANCA positive patients. Nephrology. 2011;16:725–9.CrossRef
16.
go back to reference Cui Z, Zhao J, Jia XY, Zhu SN, Zhao MH. Clinical features and outcomes of anti-glomerular basement membrane disease in older patients. Am J Kidney Dis. 2011;57:575–82.PubMedCrossRef Cui Z, Zhao J, Jia XY, Zhu SN, Zhao MH. Clinical features and outcomes of anti-glomerular basement membrane disease in older patients. Am J Kidney Dis. 2011;57:575–82.PubMedCrossRef
18.
go back to reference Stewart JH, McCredie MRE, McDonald SP. Nephrol Dial Transpl. 2004;19:678–85.CrossRef Stewart JH, McCredie MRE, McDonald SP. Nephrol Dial Transpl. 2004;19:678–85.CrossRef
Metadata
Title
Vasculitis in New Zealand
Author
Janak Rashme de Zoysa
Publication date
01-10-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0703-6

Other articles of this Issue 5/2013

Clinical and Experimental Nephrology 5/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine